| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a661fce2db0dbce3e79acdcfb53cc9f4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-541
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2011-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59f9a187590f341d1a835d05dc5d4f1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f8ae11c67004a484429b2656eb5d6a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_461c0c813b8eac55b5d23e6eeff4c50c |
| publicationDate |
2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-611654-A |
| titleOfInvention |
Treatment of jak2-mediated conditions |
| abstract |
Provided is a method for treating a patient with anaemia, comprising the administration of N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide (CYT387 or momelotinib) or a related pyrimidine containing compound of the general formula (1) where the variables are defined in the specification. An example of a related compound is 4-(5-bromo-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide. Further provided are an article of manufacture and a kit comprising CYT387 with a label or instructions related to the use of CYT387 in anaemia. Provided is an improved method for treating a subject having, or at risk of, a medical condition for which a JAK inhibitor is indicated, the method comprising selecting a subject that meets at least one of a number of criteria and administering CYT387 whereby the treated subject exhibits an anaemia and/or a spleen response that is improved relative to a subject not meeting any of the criteria. Further provided are an article of manufacture and a kit comprising CYT387 and a label or instructions related to the use of CYT387 in relation to the criteria of the improved method. |
| priorityDate |
2010-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |